The patented nanoparticle technology solubilises pharmaceutical compounds in fatty acids and/or fatty alcohols. The formulation achieves aqueous form after dilution with equimolar of protonating agent, thereby keeping the drug in the micelle of the fatty acid salt.
Formatech claimed that the technology addresses many excipient related safety issues, results in maximum tolerated doses, provides a better PK profile and delivers drug formulations compatible with parenteral, oral, pulmonary and topical administration.
Indu Isaacs, CEO of Formatech, said: “This nanoparticle technology is ideal for application to commercially successful drugs that call for a safer, more effective drug product formulation, including: Lapachone, Digoxin, N-Acetylsalicylic Acid, Taxotere, Taxol, Diprivan and Cyclosporin.
“Our first candidate under development at Formatech using this patented neunanotechnology is docetaxel. The formulation technology is also applicable to many novel hydrophobic pharmaceutical compounds and new chemical entities.”